Ratings Apex Healthcare

Equities

AHEALTH

MYL7090OO003

End-of-day quote BURSA MALAYSIA 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
3.29 MYR +2.81% Intraday chart for Apex Healthcare +10.03% +32.13%

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The company is in a robust financial situation considering its net cash and margin position.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The company benefits from high valuations in earnings multiples.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
+32.13% 496M -
+17.35% 71.39B
C+
+2.39% 25.1B
C+
-1.22% 8.59B
C
+6.69% 8.19B
B
-20.96% 7.91B
B-
-0.18% 4.54B
B-
+17.12% 4.31B
B+
-2.61% 3.86B
B
+22.08% 3.64B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality